GPCR

16.2405.14%
TW

Ted W. Love

Lead Independent Director

Dr. Ted W. Love, M.D., is Independent Director of Lisata Therapeutics, Inc. since September 17, 2026. He is a Member of Advisory Board at Syridex Bio. He is Lead Independent Director of Royalty Pharma plc from September 2025 and serves as its Independent Director since July 31, 2020. Dr. Love is Scientific advisor & director of Orca Biosystems Inc. He serves as Director since December 1, 2025 at Jazz Pharmaceuticals plc. He serves as Independent Director of Gilead Sciences, Inc. since February 2024. Dr. Love serves as the Chairman at Artbio Inc. He serves as an Independent Director of Structure Therapeutics Inc. since August 2023. He serves as Director of Seagen Inc. (formerly known as Seattle Genetics, Inc.). since August 2020. He serves as a Director of Marea Therapeutics, Inc. He serves as Independent Director at Portola Pharmaceuticals, Inc. since September 2019. Dr. Love is a recognized industry leader with experience in the discovery and development of high impact medicines. Dr. Love served as the Chief Executive Officer and President of Global Blood Therapeutics, Inc. since June 2014 until October 05, 2022. He served as a consultant in medicine in the Department of Cardiology at the Massachusetts General Hospital. Dr. Love serves as a Senior Medical Advisor of Ivivi Health Sciences, LLC. He served as a Consultant of Onyx Pharmaceuticals, Inc. from August 1, 2012 to December 31, 2012. He served as an Executive Vice President of Research & Development and Technical Operations Onyx Pharmaceuticals, Inc. from February 1, 2010 to August 1, 2012 and served as its Head of Research and Development from February 1, 2010 to January 2011 and Head of Research & Development and Technical Operations from January 2011 to August 1, 2012. He served as the President of Nuvelo Inc. from January 2001 to 2009 and its Chief Executive Officer from March 2001 to 2009. He served as the Chief Operating Officer of Nuvelo Inc. from January 2001 to March 2001. Before joining Nuvelo in 2001, he served as a Senior Vice President of Development at Theravance Inc. (formerly known as Advanced Medicine Inc.) from February 1998 to January 2001. Dr. Love worked at Genentech Inc. in a number of senior management positions in Medical Affairs and Product Development. Dr. Love served as a Research Physician and Vice President of Product Development and Regulatory Affairs at Genentech from 1992 to 1998, he oversaw all drugs in development including Herceptin (R), Rituxan(R) and TNKase(TM). He served as the Chairman of KaloBios Pharmaceuticals, Inc. since May 1, 2014 until May 2015. He served as the Chairman at Nuvelo Inc. from September 2005 to 2009. He serves as a Director of Oncothyreon. He served as a Director of Avillion LLP. He served as an Independent Director at Amicus Therapeutics, Inc. since June 13, 2012 until August 8, 2020. He Chairs the Emerging Companies Section at Biotechnology Innovation Organization and is also its board member. He served as an Independent Director of Cascadian Therapeutics, Inc. since September 06, 2013 to until March 9, 2018. He serves as a Director of California Life Sciences Association (formerly California Healthcare Institute). Dr. Love served as Director at Global Blood Therapeutics, Inc. since September 2013 until October 05, 2022. He serves as a Trustee on the board of managers of Haverford College. Dr. Love served as a Director of KaloBios Pharmaceuticals, Inc. since March 2009 until November 19, 2015 and its Lead Independent Director since May 2015 until November 19, 2015. He served as a Director of Santarus Inc. from March 18, 2005 to January 2, 2014. He served as Director of Stanford Health Care (formerly Stanford Hospital & Clinics). Dr. Love served as a Director of Affymax, Inc. from June 2006 to June 4, 2013. He served as a Director of Mast Therapeutics, Inc. from September 7, 2012 to August 6, 2013. He served as a Director of Bio-Rad Laboratories, Inc. from 2010 to April 23, 2013. He served as a Director of Anesiva, Inc. since November 23, 2009; ARCA biopharma, Inc. from February 2001 to March 22, 2011; Nuvelo Inc. from February 2001 to 2009; Predix Pharmaceuticals Holdings, Inc. since September 2003 and Predix Pharmaceuticals, Inc. He completed his Residency and Fellowship training in Internal Medicine and Cardiology at Massachusetts General Hospital and Harvard Medical School. Following residency training, he joined the faculty of Massachusetts General in the department of cardiology. Dr. Love received the William E. Proudford Sickle Cell Fund 2023 Distinguished Service Award. He also earned the Spirit of the Heart Health Equity Champion Award from the Association of Black Cardiologists in 2023. Dr. Love holds a B.A. in Molecular Biology from Haverford College at Massachusetts General Hospital and an M.D. from Yale Medical School.

公司職務